Grifols (GIFLF) Gains from Investment Securities (2010 - 2021)
Grifols (GIFLF) reported Gains from Investment Securities of $17.2 million for Q4 2021, down 15.18% on a YoY basis from $20.3 million in Q4 2020, and down 15.18% quarter-over-quarter from $20.3 million in Q4 2020.
Grifols (GIFLF) Gains from Investment Securities (2010 - 2021) Analysis & Trends
Grifols has reported Gains from Investment Securities for 11 years, with the latest figure at $17.2 million in Q4 2021.
- For the quarter ending Q4 2021, Gains from Investment Securities fell 15.18% year-over-year to $17.2 million; the trailing twelve-month figure through Dec 2021 stood at $17.2 million (down 15.18% YoY), and the FY2025 full-year result was -$2.3 million, down 117.86% from the prior year.
- Gains from Investment Securities for Q4 2021 stood at $17.2 million, down from $20.3 million in the prior quarter.
- The five-year high for Gains from Investment Securities was $20.3 million in Q4 2020, with the low at $13.2 million in Q2 2017.
- Historically, Gains from Investment Securities has averaged $15.8 million across 4 years, with a median of $14.2 million in 2018.
- Annual changes were most pronounced in 2017 — Gains from Investment Securities sank 88.65% — and 2018, when it advanced 7.95%.
- Grifols' Gains from Investment Securities stood at $13.9 million in 2017, then grew by 2.26% to $14.2 million in 2018, then surged by 42.46% to $20.3 million in 2020, then slipped by 15.18% to $17.2 million in 2021.
- The last three Gains from Investment Securities figures came in at $17.2 million (Q4 2021), $20.3 million (Q4 2020), and $14.2 million (Q2 2018), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Gsk | 96,436,181.12 Bn | 96,436,176.16 Bn | 7.76 Bn |
| 2 | Eli Lilly | 1,017.30 Bn | 1,012.01 Bn | 16.22 Bn |
| 3 | Johnson & Johnson | 579.61 Bn | 557.55 Bn | 15.96 Bn |
| 4 | AbbVie | 402.30 Bn | 392.96 Bn | 10.78 Bn |
| 5 | Merck | 294.24 Bn | 288.59 Bn | 12.09 Bn |
| 6 | Amgen | 191.82 Bn | 179.78 Bn | 5.87 Bn |
| 7 | Gilead Sciences | 155.93 Bn | 148.21 Bn | 5.52 Bn |
| 8 | Pfizer | 149.05 Bn | 136.28 Bn | -1.21 Bn |
| 9 | Bristol Myers Squibb | 116.33 Bn | 105.88 Bn | 8.07 Bn |
| 10 | Grifols | - | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2021 | 17.20 Mn |
| Dec 31, 2021 | 17.20 Mn |
| Dec 31, 2020 | 20.28 Mn |
| Dec 31, 2020 | 20.28 Mn |
| Jun 30, 2018 | 14.23 Mn |
| Jun 30, 2018 | 14.23 Mn |
| Dec 31, 2017 | 13.92 Mn |
| Dec 31, 2017 | 13.92 Mn |
| Jun 30, 2017 | 13.19 Mn |
| Jun 30, 2017 | 13.19 Mn |
| Dec 31, 2016 | 122.64 Mn |
| Dec 31, 2016 | 122.64 Mn |
| Sep 30, 2016 | 13.71 Mn |
| Sep 30, 2016 | 13.71 Mn |
| Jun 30, 2016 | 14.26 Mn |
| Jun 30, 2016 | 14.26 Mn |
| Dec 31, 2015 | -150.85 Mn |
| Dec 31, 2015 | -150.85 Mn |
| Sep 30, 2015 | 81.12 Mn |
| Sep 30, 2015 | 81.12 Mn |